---
layout: default
title: Palonosetron
parent: Model Prediction Only (L5)
nav_order: 1011
evidence_level: L5
indication_count: 5
---

# Palonosetron
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **5** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Palonosetron: From Nausea and Vomiting Prevention to Migraine Disorder

## One-Sentence Summary

Palonosetron is a 5-HT3 receptor antagonist, a class used to prevent nausea and vomiting. The TxGNN model predicts it may be effective for **migraine disorder** with a very high score, but there are currently **0 clinical trials** and **0 publications** supporting this specific prediction. It is a model-generated hypothesis only.

## Quick Overview

| Item | Content |
|------|------|
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (the five listed below are all generic ANDAs) |
| Recommended Decision | Hold |

The Evidence Pack contains no approved-indication text, so the original indication is not taken from the label data. The "nausea and vomiting prevention" framing in the title comes from general knowledge of the drug class.

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in DrugBank for this record. Palonosetron is known to be a 5-HT3 receptor antagonist. Serotonin signaling is implicated in migraine, and nausea and vomiting are among its most troublesome symptoms. This gives a plausible but unproven rationale.

The link between the original use and migraine is therefore mainly symptomatic (nausea and vomiting). Earlier 5-HT3 antagonists have not shown clear prophylactic or acute benefit in migraine, so any benefit may be limited to relieving nausea rather than treating the migraine itself.

The high TxGNN score reflects proximity in the knowledge graph, not clinical evidence. The other four predictions for this drug are weaker still:
- **Migraine with brainstem aura:** likely inherits its score from the parent migraine node.
- **Migraine with or without aura, susceptibility to:** a genetic susceptibility phenotype, not a treatable indication. Its retrieved literature covers epilepsy and migraine genetics and does not study palonosetron.
- **Atrophoderma vermiculata and ulerythema ophryogenesis:** rare follicular skin disorders with no plausible mechanistic link, most likely knowledge-graph artifacts.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## US Market Information

| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---------|------|------|-----------|
| ANDA215861 | Palonosetron Hydrochloride | Injection, solution | Meitheal Pharmaceuticals Inc. |
| ANDA206916 | Palonosetron Hydrochloride | Injection | Baxter Healthcare Corporation |
| ANDA205648 | Palonosetron | Injection | Apotex Corp. |
| ANDA204289 | Palonosetron Hydrochloride | Injection, solution | Sagent Pharmaceuticals |
| ANDA204702 | Palonosetron Hydrochloride | Injection, solution | Eugia US LLC |

All listed products are injectables.

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests only on a knowledge-graph score. There are no trials or drug-specific publications for migraine, and prior 5-HT3 antagonists have not shown clear benefit in migraine. Existing products are injectables, which may not suit migraine treatment.

**To proceed, the following is needed:**
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Preclinical or clinical evidence of palonosetron or other 5-HT3 antagonists in migraine, including nausea-specific outcomes
- Route compatibility assessment (available injectable forms versus routes needed for migraine)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

